BIOTHEUS
Live / Registered — Registered (as of 07 Nov 2023)
What this means for you
Registered since 07 Nov 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79344182
- Registration number
- 7209518
- Mark type
- Design + words
- Filed
- 14 Apr 2022
- Published for opposition
- 22 Aug 2023
- Registered
- 07 Nov 2023
- Attorney of record
- Michael T. Smith
Goods and services
- Class 005 — Pharmaceuticals: Medicines used for treating cancers; biological preparations used for treating cancer; anti-cancer pharmaceutical preparations; medicines for human purposes for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; pharmaceutical preparations for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; chemico-pharmaceutical preparations for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; medicines for medical purposes for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; chemical preparations for pharmaceutical purposes for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; biological preparations for medical purposes for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; biochemicial medicines for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; medicines in the form of injections for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases
- Class 042 — Scientific and technological services: Scientific research in the field of medication evaluation; quality control evaluation for others; scientific research in the nature of conducting clinical trials for others; scientific research in the field of antibody; services of medical laboratory
Owner
- Biotheus Inc., Zhuhai, Guangdong, CN
- Biotheus Inc., Zhuhai, Guangdong, CN
- Biotheus Inc., Zhuhai, Guangdong, CN
Prosecution history
- 04 Mar 2024 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 08 Feb 2024 — FINAL DISPOSITION NOTICE SENT TO IB
- 08 Feb 2024 — FINAL DISPOSITION PROCESSED
- 07 Feb 2024 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 07 Nov 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 07 Nov 2023 — REGISTERED-PRINCIPAL REGISTER
- 22 Aug 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 22 Aug 2023 — PUBLISHED FOR OPPOSITION
- 21 Aug 2023 — NOTIFICATION PROCESSED BY IB
- 02 Aug 2023 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 02 Aug 2023 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
- 02 Aug 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 14 Jul 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 13 Jul 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 13 Jul 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE